- Analysts
- Dividend Payments
- Government Awards
- Insiders
- Lobbying Expenses
- Segment Revenues
- Shareholder Structure
- Supply / Portfolio
- Valuation Models [Soon]
- Board & Officers
- Business Intelligence
- Employee Voice
- ESG Scores [Soon]
- Mergers and Acquisitions
- Qualified Risks
- Clinical Trials [Soon]
- H1B/PERM Strategy
- Industry H&T [Soon]
- Macro
- News
- Patents / Trademarks [Soon]
- Peer Performance
- Relevant Disputes [Soon]
CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates in…
Shareholders
Major Shareholders · StructureBreakdown
The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. for CytomX Therapeutics, Inc.
Beneficial Owners Beta
Beneficial owners who control a significant portion of the shares outstanding.
| Owner | Shares | Equivalence - $0.83 per share | Last Form/Filing | Last Transaction |
|---|---|---|---|---|
| 10% Holder | ||||
| - No data - | ||||
| Officers/Directors Below 10% | ||||
| - No data - | ||||
Shareholder Breakdown
The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public.
It's perfect to get a quick briefing regarding the shareholder structure of CytomX Therapeutics, Inc.
Short
We source Fail-To-Deliver data every month, directly from the SEC.